Page 2 - Pharmaceutical Companies

Sun Pharmaceuticals' Halol plant gets 'import alert' from USFDA

The USFDA had imposed an import ban on the Halol plant in December 2015 too

Flu season starts, but demand for cough-cold meds remains weak

Impact in US among the worst in the past 10 years

Gland Pharma stock seen underperforming after acquiring France's Cenexi

Lack of near-term visibility on profitability for the core business is another concern about Indian firm

Gland Pharma to acquire French firm Cenexi Group for Rs 1,000 crore

Will fund transaction from internal accruals

Bharat Bio looks for partners to manufacture, distribute iNCOVACC globally

Its local production ramp-up remains unhurried as demand for boosters reduces

Indian pharma exports rise by 4.22% to $14.57 bn during April-Oct

Pharmaceutical exports from India registered a growth of 4.22 per cent to reach USD 14.57 billion during the April-October period despite a negative trend last month, according to a senior official of an export promotion body under Government of India. Udaya Bhaskar, Director General of Pharmaceuticals Export Promotion Council of India (Pharmexcil) which is an organisation under the Ministry of Commerce, said he was hopeful of ending the current fiscal at around USD 27 billion as against USD 24.62 billion during the last financial year. "There was a dip (-0.32 per cent) in July and (-5.45 per cent) and there was 8.47 per cent positive growth in September. I am optimistic that it will be revived in the coming months and may touch USD 27 billion at the end of the fiscal," Bhaskar told PTI. During the same period last fiscal, the exports fetched USD 13.98 billion. USA, Canada and Mexico (NAFTA countries), Europe and Africa account for 67.5 per cent (nearly USD 5 billion) of the total

China-Plus-One strategy: Indian API firms start to reap benefits

Rising Chinese labour costs, geopolitics, pandemic-stricken uncertainties have forced global players to derisk

Top Headlines: Oz parliament okays FTA with India, RBI rate hike & more

The Australian Parliament on Monday ratified the Economic Cooperation and Trade Agreement (ECTA) with India, paving the way for implementing the deal as early as January 1, 2023

World in turmoil, domestic pharma firms target India for healthy growth

Share of India revenue in home-grown firms' consolidated turnover rising over the years

Inflows in Tata Motors stock may surge as it replace Dr Reddy's in Sensex

Change effective from Dec 19, but adjustment will take place on Dec 16. After DRL's deletion, Sun Pharma will be the only healthcare stock in the index

Trying to lock in vendors who don't want to buy from China: Biocon CEO & MD

Siddharth Mittal, CEO & MD, Biocon, elaborates on his plans to grow this business further

Sun Pharma's Mohali plant in Punjab receives OAI status from USFDA

The plant was inspected in August and had received a form 483 with six observations earlier

Cipla Q2 PAT up 11% PAT to Rs 789 cr on strong Covid-adjusted growth rate

The company is de-risking key product Abraxane in case the Goa plant FDA issue is not cleared immediately

India looking at greater market access for pharma products in UK under FTA

India is looking at greater market access for its pharmaceutical products in the UK as part of the proposed free trade agreement with Britain, an official said on Friday. The official also said that a leaked chapter of the agreement, which is floated on some portals, on intellectual property (IP) is edited, distorted, and is a manipulated version of an initial document of the UK. "The best part in the proposed agreement is that both sides have highlighted their red lines and sensitivities. Ever-greening and touching manufacturing of generic medicines is completely non-negotiable," the official added. India has already secured greater market access for the domestic pharma industry in a trade pact with the UAE. Under the pact, Indian pharmaceutical products and medical goods will get regulatory approval within 90 days that have been approved in developed jurisdictions such as the US, the UK, the EU, Canada, and Australia. Similarly, the India-Australia trade deal would provide ...

Chhattisgarh govt's flagship scheme delivers hefty markdown on medicines

The state government has given priority to the health security of the people, the official said

Sun Pharma Q2 PAT rises 10.5% YoY to Rs 2,262 crore on robust sales

Gross sales came in at Rs 10,809.2 crore, growing by 13.1% over Q2 last year

Q2FY23 preview: Modest revenue growth, Ebitda decline seen in pharma cos

While domestic market demand is strong, analysts expect higher raw material and freight costs to affect business in US, other countries; healthy YoY growth seen in hospitals and diagnostics

Drug regulator halts production at Maiden Pharma's Sonipat unit

Centre forms panel to analyse causal relation between deaths and cough syrups

Haryana stops production at plant making cough syrups flagged by WHO

12 violations found at Maiden Pharmaceuticals' Sonipat facility, says state health minister

Gambia police link child deaths to cough syrup imported by US firm

The deaths of 69 children from acute kidney injury in Gambia is linked to four cough syrups made in India and imported into the West African country via a US-based pharma firm, the Gambian police said